| [11C]AZ1419 3391 + Palacaparib for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| [11C]AZ1419 3391 + Palacaparib for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| [11C]AZ1419 3391 + Palacaparib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| [11C]AZ1419 3391 + Palacaparib + Temozolomide for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| [11C]AZ1419 3391 + Palacaparib + Temozolomide for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| [11C]AZ1419 3391 + Palacaparib + Temozolomide for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| [68Ga]Ga-OncoACP3 for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| 130 mCi NYMO32 + 200 mCi NYMO32 + 30 mCi NYMO32 + 50 mCi NYMO32 + 80 mCi NYMO32 for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| 186RNL for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| 5-FU, Leucovorin, Oxaliplatin, Docetaxel for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| 61Cu-NODAGA-LM3 + Comparator for neuroendocrine tumors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| 68-Gallium DOTATATE for neuroectodermal tumors, primitive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| 68-Gallium DOTATATE for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha) for penile neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ABBV-706 + ATEZOLIZUMAB + Alveltamig for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Abemaciclib for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Abemaciclib for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Abemaciclib + Irinotecan + Temozolomide for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Abemaciclib + Irinotecan + Temozolomide for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ABIRATERONE ACETATE + Prednisone for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| abiraterone acetate with prednisone + Tinengotinib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Accelerated Hypofractionated Radiation Therapy for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Acetaminophen (or equivalent) + Dexamethasone (or equivalent) + Histamine H1 Receptor Antagonist + Histamine H2 Receptor Antagonist + MK-2010 + Steroid mouthwash (dexamethasone or equivalent) + Sacituzumab tirumotecan + Epinephrine for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Actinium Ac-225 Vipivotide Tetraxetan for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Acupuncture + Questionnaires for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adaptive Hypofractionated Radiotherapy for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adaptive Hypofractionated Radiotherapy for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adaptive Hypofractionated Radiotherapy for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adebelimab Combined with Apatinib for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adebrelimab for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adebrelimab Combined With Albumin Paclitaxel for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + Nogapendekin Alfa Inbakicept + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AK105 and anlotinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aldara - Imiquimod 5% + IDH1R132H-vac for astrocytoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aldara - Imiquimod 5% + IDH1R132H-vac + Vorasidenib hemicitric acid hemihydrate for astrocytoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Allogeneic genetically modified gamma-delta T cells for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Alpelisib for lymphangioma, cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 10 J/cm2) for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 20 J/cm2) for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AMXI-5001:Dose Escalation Phase I + AMXI-5001:Dose Expansion Phase II for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anastrozole placebo + Letrozole placebo + CAMIZESTRANT for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Apalutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy (ADT) + Placebo for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen deprivation therapy (ADT) + SRT + REZVILUTAMIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Deprivation Therapy + Apalutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen Receptor Signal Inhibitor (ARSI) + Luteinizing Hormone-Releasing Hormone (LHRH) analog + DOCETAXEL for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen receptor signaling inhibitor (ARSI) + VIR-5500 for prostatic neoplasms, castration-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Androgen receptor signaling inhibitor (ARSI) + VIR-5500 + DOCETAXEL for prostatic neoplasms, castration-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| anti-PD1 agent therapy - 1 year for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| anti-PD1 agent therapy - 2 years for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Apalutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Apatinib+Camrelizumab+SOX + Preoperative Radiotherapy for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| APG-157 for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for rhabdomyosarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for sarcoma, ewing | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ART6043 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ART6043 + Olaparib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ASP2998 for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ASP2998 + Carboplatin + ENFORTUMAB VEDOTIN + PEMBROLIZUMAB for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ASP3082 for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aspirin for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atezolizumab for carcinoma, neuroendocrine | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atezolizumab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atezolizumab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atezolizumab for neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Atezolizumab for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATEZOLIZUMAB + Divarasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATEZOLIZUMAB + Doxorubicin hydrochloride for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATEZOLIZUMAB + Vincristine + Irinotecan + Temozolomide for rhabdomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atorvastatin for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atorvastatin + Aspirin for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lung | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AUR103 Calcium for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for glioblastoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for gliosarcoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for oligodendroglioma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for glioblastoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for gliosarcoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for oligodendroglioma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Autologous genetically modified gamma-delta T cells for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Autologous hALK.CAR T cells for neuroblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous NK cell plus GD2 antibody for neuroblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Autologous testicular tissue transplantation of prepubertal frozen testicular tissue for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for fallopian tube neoplasms | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for neoplasm metastasis | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Avelumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Avelumab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Avelumab for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Axelopran + pembrolizumab for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Axelopran + pembrolizumab for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Axitinib + AVELUMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD6750 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD6750 + Rilvegostomig for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD8205 and AZD2936 (Rilvegostomig) for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD8205 and AZD5305 (saruparib) + AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD8205 in combination with AZD9574 + AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azenosertib for uterine neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azithromycin + Hydroxychloroquine for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| B1962 for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Balstilimab + evofosfamide + zalifrelimab for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Balstilimab + evofosfamide + zalifrelimab for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Becotatug for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Becotatug Vedotin for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Berzosertib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bevacizumab for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BEVACIZUMAB + Divarasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bevacizumab + nivolumab for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bevacizumab + nivolumab + relatlimab for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bevacizumab + nivolumab + rucaparib for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bevonescein (ALM 488) Infusion for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bexmarilimab for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bezuclastinib for soft tissue neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BHB810 for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| bi-4SCAR GD2/CD70 T cells for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for gliosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy + Cystoscopy + Bone Scan + Digital Rectal Examination + MRI-Guided Transurethral Ultrasound Ablation + Multiparametric Magnetic Resonance Imaging + PSMA PET Scan + Questionnaire Administration for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, basosquamous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Multigated Acquisition Scan + Radiologic Imaging Procedure + PIDNARULEX + TRASTUZUMAB DERUXTECAN for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Computed Tomography + Gallium Ga 68 Gozetotide + Positron Emission Tomography + Questionnaire Administration + Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Diagnostic Imaging Testing + Excisional Biopsy + Minimally Invasive Surgery + Pelvic Lymphadenectomy + Questionnaire Administration + Sentinel Lymph Node Mapping + Indocyanine Green for carcinosarcoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN + OMEGA-3-ACID ETHYL ESTERS for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Blinatumomab for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| BLINATUMOMAB + Venetoclax for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Blood Sample + Cerebrospinal Fluid (CSF) Sample + Chemotherapy Drug, Cancer - Physician's Choice + Non-Investigational Surgical Resection + Radiotherapy (RT) + Tumor Tissue Sample + Temozolomide for neuroectodermal tumors, primitive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BMX-001 for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BNT329 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BNT329 + CA19-9-targeting monoclonal antibody for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brachytherapy for osteosarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brachytherapy + External Beam Radiotherapy (EBRT) + NIMOTUZUMAB + CISPLATIN for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brachytherapy + External Beam Radiotherapy (EBRT) + placebo for Nimotuzumab + CISPLATIN for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brain surgery + RETIFANLIMAB + RAGIFILIMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brain surgery + SRS + RETIFANLIMAB + RAGIFILIMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Breast Radiotherapy for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Burning Pain + Myofascial Pain + Neuralgia Pain + Orofacial Bone Pain + Persistent Pain for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cabozantinib for carcinoid tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cabozantinib for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cabozantinib + BEVACIZUMAB + ATEZOLIZUMAB + EMACTUZUMAB + RUCAPARIB + SIMLUKAFUSP ALFA + ALECTINIB for neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cabozantinib + NIVOLUMAB for carcinoid tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cabozantinib + NIVOLUMAB + IPILIMUMAB for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cadonilimab for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cadonilimab + lenvatinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| camrelizumab; famitinib malate for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capecitabine for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capecitabine for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capecitabine + pembrolizumab for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| capecitabine or 5-FU + Intensity Modulated Radiation Therapy (IMRT) + DOSTARLIMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capivasertib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capivasertib for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capivasertib for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capivasertib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carbon ion irradiation for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin for vulvar neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB + Paclitaxel for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB + Paclitaxel for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB + Paclitaxel for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + NAB-PACLITAXEL for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + NAB-PACLITAXEL + Cetuximab + CISPLATIN for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + Paclitaxel for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin-Paclitaxel for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin-Paclitaxel for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cardio-Oncology Referral for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cemiplimab for penile neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ceralasertib + Olaparib for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy + FAMITINIB L-MALATE + CAMRELIZUMAB for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy + Hypofractionated external beam radiation + Image-guided brachytherapy for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy + MAPK inhibitors + ARSENIC TRIOXIDE for neuroblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy TIP for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy TIP for penile neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Circulating tumor DNA (ctDNA) testing + Datopotamab Deruxtecan for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cisplatin for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Clinical decision support tool for hemangioma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Clinical decision support tool for nevus, pigmented | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Clofutriben for acth syndrome, ectopic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Clomiphene Citrate 25mg for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Combination 5-azacytidine and nivolumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Community Treatment for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| concurrent chemotherapy + Definitive hypofractionated intensity-modulated radiation theraphy for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Continuous, hyperfractionated, accelerated radiotherapy(CHART) for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Conventional Surgery + Intensity-Modulated Radiation Therapy + Quality-of-Life Assessment + Trametinib + PEMBROLIZUMAB + DABRAFENIB for thyroid carcinoma, anaplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Core Biopsy + Questionnaire Administration + AFIMOXIFENE for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Counseling + Questionnaire Administration + Psilocybin for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CP-383 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CP-383 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CR-002 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CR-002 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CR-002 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CTX-471 + Tovecimig for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide + VINORELBINE for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CYP Cocktail + ZIPALERTINIB for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytokine support + EB-PT-CAR-NK-D + EB-PT-CAR-NK-S + Lymphodepleting chemotherapy for neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| D Vitamin for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dabrafenib and trametinib (combination) for ameloblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dabrafenib, trametinib, nivolumab for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| dabrafenib/trametinib for thyroid carcinoma, anaplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dacarbazine for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dalpicilib combined with cetuximab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Daraxonrasib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Daraxonrasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Darolutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Datopotamab Deruxtecan for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Definitive radiotherapy for dermatofibrosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Definitive radiotherapy for histiocytoma, malignant fibrous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Definitive radiotherapy for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Definitive radiotherapy for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Definitive radiotherapy for sarcoma, synovial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| dendritic cell vaccine therapy + fludeoxyglucose F 18 + laboratory biomarker analysis + NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL + positron emission tomography + FLUDARABINE PHOSPHATE + Cyclophosphamide + ALDESLEUKIN for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dexamethasone/Dexamethasone acetate + Fludrocortisone/ Fludrocortisone acetate + Rescue Medications + Opevesostat for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Diane-35 + N-METHYL-N-ETHYLTRYPTAMINE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dibotatug for lymphoma, extranodal nk-t-cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Digoxin for neoplastic cells, circulating | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Disitamab for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Disitamab + ENVAFOLIMAB for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Divarasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Divarasib + Cetuximab for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Divarasib + ERLOTINIB for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Divarasib + Inavolisib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| dMD-002 for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| DOCETAXEL + Hydroxychloroquine + Gemcitabine for osteosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dose-escalated radiation therapy for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dose-intensified Accelerated Photon Beam Radiation Therapy for glioblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dose-intensified Photon Beam Radiation Therapy for glioblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dostarlimab for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dostarlimab for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Doublet Chemotherapy, Dose-reduced (75%) for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Doxorubicin hydrochloride + ELRAGLUSIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Doxorubicin hydrochloride + ELRAGLUSIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Doxorubicin hydrochloride + ELRAGLUSIB for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab for neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| DURVALUMAB + Datopotamab Deruxtecan for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + Gem/Cis for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + oleclumab for hemangiosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + oleclumab for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + oleclumab for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, synovial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Echocardiography Test + Doxorubicin hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Educational and Media Intervention for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Eflornithine for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| EGCG and Quinine Sulfate Vaginal Suppository for atypical squamous cells of the cervix | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELI-002 2P for cholangiocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELI-002 2P for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Eliminating RT to the elective neck for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elironrasib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elironrasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elironrasib + Daraxonrasib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elironrasib + Daraxonrasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elraglusib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elraglusib for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elraglusib for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + Gemcitabine Hydrochloride for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + Gemcitabine Hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + Gemcitabine Hydrochloride for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ENABLE Cornerstone for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enfortumab vedotin + pembrolizumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enlonstobart for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enoblituzumab for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Enzalutamide + Mevrometostat for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide + Mevrometostat for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide + PEMBROLIZUMAB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide + Tinengotinib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ERAS-601 for chordoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Erdafitinib + cetrelimab for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ETX-19477 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ETX-19477 for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Evorpacept for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Exercise Intervention for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Exercise Therapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Experimental for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for gliosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for gliosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FAPi-46 GA-68 for carcinoma, signet ring cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FAPi-46 GA-68 for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Farletuzumab ecteribulin for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Farletuzumab ecteribulin for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Fasudil hydrochloride combined with immunotherapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE + Temozolomide for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FLUDEOXYGLUCOSE F-18 + PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Fluzoparib with Temozolomide for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FMC-376 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FMT capsule for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical) for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Focal One high intensity focused ultrasound device for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Folfoxiri for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Folfoxiri for neoplastic cells, circulating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Fulvestrant + CDK4/6i + Capivasertib for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Exemestane for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Tersolisib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Tersolisib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Tersolisib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GALLIUM GA-68 GOZETOTIDE for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GALLIUM GA-68 GOZETOTIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| GALUNISERTIB + Enzalutamide for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GCP intratumoral catheter for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Gecacitinib + ZG005 + BEVACIZUMAB for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Gemcitabine + ERLOTINIB + NAB-PACLITAXEL for neoplasms, basal cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Gemcitabine Hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + BEVACIZUMAB + Paclitaxel for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + BEVACIZUMAB + Paclitaxel for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + Doxorubicin for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + Doxorubicin for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + Eribulin for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + Eribulin for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + PEMBROLIZUMAB for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + PEMBROLIZUMAB for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + TRASTUZUMAB DERUXTECAN for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + TRASTUZUMAB DERUXTECAN for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 subcutaneous (SC) for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 subcutaneous (SC) for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-108 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-108 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Glucagon-like peptide 1 receptor agonist for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GnRH agonist and Letrozole + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GnRHa + Letrozole for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Green tea leaf for leiomyoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GSK5471713 for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GT101 + HUMAN INTERLEUKIN-2 for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hafnium oxide for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hafnium Oxide-containing Nanoparticles NBTXR3 + Radiation Therapy for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Haic+tae + tislelizumab + surufatinib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Harm Reduction (E-cigarette switching) for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High Dose Rate Brachytherapy + intra-lesional boost IMRT for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High Dose Rate Brachytherapy + intra-lesional boost IMRT for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Histotripsy for abdominal neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| HRS-1167 tablets + Prednisone Acetate tablets + ABIRATERONE ACETATE for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| HS-20093 for osteosarcoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hybrid Palliative Radiation Therapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hydroxychloroquine for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hypofractionated re-irradiation + MANNITOL + Cetuximab for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IA Carboplatin + IA Caelyx for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IA Carboplatin + IA Etoposide Phosphate for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IBI310 + SINTILIMAB + SURUFATINIB for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IDH1 peptide vaccine for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IDH1-vac for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IDH1R132H peptide vaccine for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IDH1R132H peptide vaccine + AVELUMAB for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Idroxioleate Sodium for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ifinatamab deruxtecan for neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IMNN-001 for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) for fallopian tube neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| INCA33890 for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| INR101 for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Intensity-modulated radiation therapy (IMRT) for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Internet-Based Intervention + Quality-of-Life Assessment + Questionnaire Administration for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Iparomlimab and Tuvonralimab (QL1706) for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ipatasertib + atezolizumab for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ipilimumab for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan + ELRAGLUSIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan + ELRAGLUSIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan + ELRAGLUSIB for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan + Temozolomide for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan + Temozolomide for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan hydrochloride + bevacizumab for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IRINOTECAN HYDROCHLORIDE + BEVACIZUMAB + LEUCOVORIN + Fluorouracil for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma for sarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irradiation + Surgical resection + PEGFILGRASTIM + Vincristine + ETOPOSIDE + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Iscador*P for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Iscador*P for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivermectin + Losartan for neoplasms | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivonescimab for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivonescimab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivosidenib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivoximab 20 mg/kg, ivgtt, Q4W + Temozolomide for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Izalontamab Brengitecan for carcinoma, transitional cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| JBI-778 for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| JK-1201I + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| JNJ-101556143 for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| JSKN033 + BEVACIZUMAB + PLATINUM for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ketamine for head and neck neoplasms | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ketamine Hydrochloride for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ketoprofen for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| KLH-2109+ Leurprorelin acetate Placebo for leiomyoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolar | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolar | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, alveolar | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, embryonal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for gliosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Larotrectinib for neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lenvatinib for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lenvatinib + farletuzumab ecteribulin for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lenvatinib + farletuzumab ecteribulin for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for liposarcoma, myxoid | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for sarcoma, synovial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Leucovorin for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lifileucel for histiocytoma, malignant fibrous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lifileucel for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Local Therapy + Standard Therapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Loco-regional radiotherapy for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Loco-regional radiotherapy for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lomustine + ELRAGLUSIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lomustine + ELRAGLUSIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lomustine + ELRAGLUSIB for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lorigerlimab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Losartan + Paclitaxel for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Low Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Low-Dose Radiation Therapy (LDRT) for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Low-dose Radiotherapy + SINTILIMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lurbinectedin for leiomyosarcoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lurbinectedin for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
|---|
| LUTETIUM OXODOTREOTIDE LU-177 for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LY3537021 for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| M032 + PEMBROLIZUMAB for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| M032 + PEMBROLIZUMAB for gliosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Hypofractionated Radiation Therapy + Positron Emission Tomography + Survey Administration for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Positron Emission Tomography + Stereotactic Body Radiation Therapy + Survey Administration for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Bone Marrow Aspiration + Bone Marrow Biopsy + Clinical Observation + Computed Tomography + Ultrasound + ETOPOSIDE + Doxorubicin hydrochloride + Cyclophosphamide + Carboplatin for ganglioneuroblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolar | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, acinar cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, giant cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for chordoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, serous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for desmoid tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for hemangiosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for paget disease, extramammary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for perivascular epithelioid cell neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pheochromocytoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pseudomyxoma peritonei | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for seminoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for vulvar neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolar | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, acinar cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, giant cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for chordoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, serous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for desmoid tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for hemangiosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for paget disease, extramammary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for perivascular epithelioid cell neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pheochromocytoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pseudomyxoma peritonei | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for seminoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for vulvar neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine + Carboplatin for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Lumbar Puncture + Radiation Therapy + Dabrafenib Mesylate + TRAMETINIB DIMETHYL SULFOXIDE for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Clinical Observation + Computed Tomography + Ultrasound for ganglioneuroblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Laboratory Biomarker Analysis + Radiation Therapy + Vincristine + Lomustine + Cyclophosphamide + CISPLATIN + Vincristine Sulfate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Multiparametric Magnetic Resonance Imaging + Positron Emission Tomography + Transrectal Ultrasonography Guided Biopsy + Flotufolastat F-18 Gallium for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Maximal surgical resection + Radical radiotherapy + Stupp regimen (oral temozolomide) + THIOTEPA for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mazdutide for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Medium Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Megestrol acetate/Medroxyprogesterone acetate + TAMOXIFEN + Letrozole for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mesna + Paclitaxel + Ifosfamide for neoplasms, germ cell and embryonal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Metformin for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Metformin hydrochloride for medulloblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Methadone for leiomyoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| mFOLFOXIRI for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Migoprotafib + Divarasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mirvetuximab Soravtansine for fallopian tube neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
|---|
| Mirvetuximab Soravtansine for neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mitomycin for pseudomyxoma peritonei | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| MK-3120 for neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ML-016 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Molecularly matched therapy for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Monotherapy, Dose-reduced (75%) for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| MR-Guided Transurethral US Ablation of Prostate Tissue for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| MRI-Guided Transurethral Ultrasound Ablation for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mupirocin Ointment [Treatment] for head and neck neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| n-dodecyl-B-D-maltoside + Cretostimogene Grenadenorepvec for carcinoma, transitional cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| N17350 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| N17350 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nab-paclitaxel for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nab-paclitaxel + Gemcitabine + VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NanoKnife System for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Navitoclax for neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Navlimetostat for mesothelioma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Naxitamab for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Near-infrared fluorescence imaging + Indocyanine Green for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Neoadjuvant chemotherapy instead of upfront surgery for neoplastic cells, circulating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Neoadjuvant Radiation + Surgery + TALIMOGENE LAHERPAREPVEC for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NeuroSAFE procedure for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niacinamide for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nilotinib and Paclitaxel for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NIMOTUZUMAB + Ivonescimab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nimotuzumab, Benmelstobart for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niraparib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niraparib for glioblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niraparib for mesothelioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niraparib for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab & Ipilimumab + Zirdafulven for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NIVOLUMAB + Catequentinib for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + daratumumab for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + ipilimumab for head and neck neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + ipilimumab for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + ipilimumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + ipilimumab + trabectedin for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + relatlimab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + Relatlimab + CAPECITABINE for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + rucaparib for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NIVOLUMAB + Temozolomide for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NIVOLUMAB + Trametinib + IPILIMUMAB for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab and Ipilimumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NSAI + CDK4/6i + Capivasertib for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nutritional Assessment + Short-Term Fasting + Metformin hydrochloride for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Observation for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Off-label ICI(s) with targeted therapy for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| OK-432 for carcinoma in situ | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
|---|
| Olaparib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Olaparib for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Oleclumab for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Olomorasib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Olomorasib + PEMBROLIZUMAB + Cetuximab for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Omeprazole 80 mg twice daily for prostatic neoplasms, castration-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ommaya/VPS + Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| OncoSignature + Prexasertib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| OncoSignature + Prexasertib + Gemcitabine for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| One or more off-label ICIs alone or with other on-label ICI(s) for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Onfekafusp alfa for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Onfekafusp alfa for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Optune System + PEMBROLIZUMAB + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| OR502 + CEMIPLIMAB for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Osilodrostat for acth syndrome, ectopic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Osimertinib for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| OSIMERTINIB + Patritumab Deruxtecan for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Osimertinib + Savolitinib for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Osimertinib + Savolitinib for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| OXALIPLATIN + LEUCOVORIN + Fluorouracil for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxcel Q3W for adenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel for adenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| paclitaxel combined with platinum for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib for sarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib for sarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Padeliporfin for carcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
|---|
| Padeliporfin for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
|---|
| Palacaparib for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Datopotamab Deruxtecan for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Datopotamab Deruxtecan for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Datopotamab Deruxtecan for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Temozolomide for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Temozolomide for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Temozolomide for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Panitumumab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Partial or total penectomy with inguinal and/or pelvic lymph node dissection + PEMBROLIZUMAB + PYRUVATE CARBOXYLASE, MITOCHONDRIAL for penile neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Patritumab Deruxtecan for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Patritumab Deruxtecan for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Patritumab Deruxtecan for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Patritumab Deruxtecan for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PD-1 Inhibitors + Mitoxantrone Hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PD-1antibody plus GEMOX for klatskin tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PD1+ TILs (NUMARZU-001) product infusion for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pegylated liposomal doxorubicin + TOPOTECAN + Paclitaxel for fallopian tube neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for carcinosarcoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for leukoplakia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Pembrolizumab + lenvatinib for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PEMBROLIZUMAB + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab + nesuparib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PEMBROLIZUMAB + Paclitaxel for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed + AVELUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed + Carboplatin + Olomorasib + PEMBROLIZUMAB + Cetuximab + CISPLATIN for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for carcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peptide vaccine IPX for rhabdomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peptide vaccine IPX for sarcoma, ewing | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peptide vaccine IPX for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Perillyl alcohol for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PET/CT + FLUDEOXYGLUCOSE F-18 + [18F]-FAPI-74 for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Petosemtamab for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| PF-08634404 for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PF-08634404 + ENFORTUMAB VEDOTIN for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phentermine / Topiramate Extended Release Oral Capsule [Qsymia] for craniopharyngioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PIFLUFOLASTAT F-18 for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pirfenidoneone for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo (for Syntocinon) + Oxytocin for craniopharyngioma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo + Metformin for medulloblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ponsegromab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pravastatin (drug) for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prexasertib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prexasertib + Gemcitabine for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| prifetrastat in combination with fulvestrant for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| prifetrastat monotherapy for 15 days then combination with fulvestrant for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PRL3-zumab for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prophylactic External Beam Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prostate Radiotherapy + Radical Prostatectomy for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prostate Radiotherapy + Radical Prostatectomy for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for dermatofibrosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for glomus tumor | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for granular cell tumor | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for hemangioendothelioma, epithelioid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for hemangiosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for histiocytoma, malignant fibrous | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for leiomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for liposarcoma, myxoid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for myoepithelioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for osteosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for sarcoma, clear cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for glomus tumor | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for granular cell tumor | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for hemangioendothelioma, epithelioid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrous | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for myoepithelioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for glomus tumor | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for granular cell tumor | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for hemangioendothelioma, epithelioid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrous | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for myoepithelioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Psilocybin for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
|---|
| PSMA-guided Salvage Radiation for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Psychotherapy + Survey Administration + Psilocybin for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PUCOTENLIMAB + Becotatug Vedotin for penile neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pulmonary segmentectomy for adenocarcinoma of lung | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Puxitatug Samrotecan for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Puxitatug Samrotecan for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| QLH12016 + Enzalutamide + ABIRATERONE ACETATE for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for dermatofibrosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for histiocytoma, malignant fibrous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for sarcoma, synovial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Questionnaire Administration + Dordaviprone + Paclitaxel for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Questionnaires + Waitlist Control for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiation Therapy for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiation Therapy for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiation Therapy + OXALIPLATIN + DOCETAXEL + LEVOLEUCOVORIN + PEMBROLIZUMAB + Fluorouracil for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiation Therapy + Radical Prostatectomy for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| radical surgery + CAMRELIZUMAB + Paclitaxel + CISPLATIN for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiodynamic therapy + AMINOLEVULINIC ACID HYDROCHLORIDE for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy + CISPLATIN for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy + TRABECTEDIN for leiomyosarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy + TRABECTEDIN for liposarcoma, myxoid | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy in painting dose on histoscannographic mapping for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| radium Ra 223 dichloride + Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Olaparib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Regorafenib for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Regorafinib for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Relacorilant + nab-paclitaxel for fallopian tube neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Relugolix for leiomyoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Relugolix for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Reproductive organ sparing radical cystectomy for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rescue medications + Sacituzumab tirumotecan for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rimegepant for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Risvutatug rezetecan (Ris-Rez) for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| RITUXIMAB + LENALIDOMIDE + Acalabrutinib for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Robot-Assisted Radical Prostatectomy + ALLOGENEIC HUMAN AMNION/CHORION MEMBRANE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rocuronium 1.5mg/kg/hr for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rucaparib for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ruxolitinib + NAVITOCLAX for neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| S-1 + Irinotecan for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab + cisplatin for uterine neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab govitecan for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab govitecan for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Sacituzumab govitecan for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Sacituzumab tirumotecan for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab tirumotecan for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab tirumotecan for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab tirumotecan for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab tirumotecan for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Savolitinib + Placebo for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Savolitinib + Placebo for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sbrt for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sbrt for neuroendocrine tumors | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Segmentectomy for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Selective coverage radiotherapy for thyroid carcinoma, anaplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Selinexor for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Selinexor for rhabdoid tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Selinexor, anti-PD-1 antibody plus Golidocitinib for lymphoma, extranodal nk-t-cell | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Selpercatinib for carcinoma, medullary | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Sequential cytoreductive intervention for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Serplulimab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SHR-A1811 Injection for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SI-B003 + Izalontamab for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sigvotatug Vedotin for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Sigvotatug Vedotin for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sintilimab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SINTILIMAB + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Siremadlin + PAZOPANIB for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sirolimus for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SOC plus trastuzumab and pembrolizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonesitatug Vedotin for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonesitatug Vedotin + Rilvegostomig for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for gliosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sotorasib for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for mesothelioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for neoplasms, unknown primary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Srs + retifanlimab + ragifilimab for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + Bemarituzumab for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + DEPATUXIZUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + NIVOLUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + RAMUCIRUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + TRASTUZUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard of Care (SOC) for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard of Care SBRT and ADT + ABIRATERONE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard of Care SBRT and ADT + Atorvastatin + ABIRATERONE for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard of Care Surgery + NIVOLUMAB for head and neck neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard of Care Surgery + NIVOLUMAB + IPILIMUMAB for head and neck neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| standardized exercize program + Standardized nutritional program + Whey protein supplement with added leucine and β-hydroxy-β-methylbutyrate (HMB) for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| stereotactic ablative radiotherapy + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| stereotactic ablative radiotherapy + TESTOSTERONE + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Stereotactic Body Radiation Therapy (5 days) + Surgical Resection + PEMBROLIZUMAB for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Subventricular Zone radiation for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sugemalimab for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sunitinib for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Surufatinib Combined With Temozolomide and S-1 for neuroendocrine tumors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SXRN Injection for neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6002 for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6002 + Becotatug + Enlonstobart for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6002 + Enlonstobart for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6010 injection + Enlonstobart for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6010 injection + PEMBROLIZUMAB for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAGRAXOFUSP + Azacitidine + Venetoclax for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Talazoparib + avelumab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| talazoparib plus enzalutamide for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Talimogene Laherparepvec (T-VEC) for carcinoma, squamous cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Talimogene laherparepvec + nivolumab + trabectedin for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tamoxifen for carcinoma, intraductal, noninfiltrating | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tamoxifen for neoplasm recurrence, local | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tarlatamab for carcinoma, neuroendocrine | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Tarlatamab + Temozolomide for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Telesurgery utilizing Microport Medbot Robotic Platform for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Telisotuzumab vedotin for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Telpegfilgrastim for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Temozolomide for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Temozolomide for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Terbium 161- PSMA I&T for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tersolisib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tersolisib for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tersolisib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tersolisib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Testosterone for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Therapeutic Intervention for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tiragolumab and atezolizumab for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tisagenlecleucel for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for mesothelioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for neoplasms, unknown primary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| Tislelizumab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab+liposomal doxorubicin+ifosfamide for desmoplastic small round cell tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab+liposomal doxorubicin+ifosfamide for hemangiosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab+liposomal doxorubicin+ifosfamide for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab+liposomal doxorubicin+ifosfamide for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tki + blinatumomab for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TOCOPHEROL + Pentoxifylline for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Topical application of Periplaneta americana-derived Meilian Fuxin Solution for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Topotecan + toripalimab for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tovecimig for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + DABRAFENIB for ameloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + DABRAFENIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + DABRAFENIB for thyroid carcinoma, anaplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib and Nivolumab for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| transarterial radioembolization + CAPECITABINE + Temozolomide for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Transporter Cocktail + ZIPALERTINIB for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trastuzumab deruxtecan for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trastuzumab deruxtecan for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TRASTUZUMAB DERUXTECAN + Palacaparib for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TRASTUZUMAB DERUXTECAN + Palacaparib for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TRASTUZUMAB DERUXTECAN + Palacaparib for prostatic neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TRASTUZUMAB DERUXTECAN + Rilvegostomig for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| treatment with focal HIFU for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tremelimumab for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TREMELIMUMAB + Olaparib for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tretinoin for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tretinoin for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tretinoin for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Triptorelin pamoate for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TTP-ICG fluorescent probe for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TULSA Procedure for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tulsa-pro for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TYRA-300 for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TYRA-300 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| UBAMATAMAB + Ubletamig + SARILUMAB for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| UBAMATAMAB + Ubletamig + SARILUMAB for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Upifitimab rilsodotin for fallopian tube neoplasms | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Utidelone capsule 35mg/m2/d BID for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Utidelone capsule 40mg/m2/d BID for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Utidelone capsule 50mg/m2/d BID for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Utidelone capsule 75mg/m2/d QD for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Valacyclovir for head and neck neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vebreltinib for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vinorelbine for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VIR-5500 for prostatic neoplasms, castration-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| vitamin D 25(OH)D for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| vitamin D 25(OH)D for prostatic neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VLS-1488 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VLS-1488 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 100 mg Tablet for carcinoma, adenoid cystic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 100 mg Tablet for mesothelioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 100 mg Tablet for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 100 mg Tablet for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cystic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 Tablet and Pembrolizumab (200 mg) for mesothelioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 Tablet and Pembrolizumab (200 mg) for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for adenocarcinoma, clear cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for prostatic neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vusolimogene Oderparepvec for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Xaluritamig for prostatic neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Xiaochaihu Granules (Low Dose) for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| XON7 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| XPO1 inhibitor for lymphoma, extranodal nk-t-cell | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zanzalintinib for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| zevor-cel for carcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for head and neck neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zidesamtinib (NVL-520) for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zipalertinib for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zirdafulven for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zirdafulven + Olaparib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zolbetuximab for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zymosan + α-lactalbumin vaccine for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|